Evinacumab

Evinacumab

Monoclonal antibody
Type	?
Source	Human
Target	Angiopoietin-like 3 (ANGPTL3)
Clinical data
Other names	REGN1500
Routes of administration	subcutaneously (SC) or intravenously (IV)
ATC code	none
Identifiers
CAS Number	1446419-85-7
ChemSpider	none
UNII	T8B2ORP1DW
KEGG	D11753
Chemical and physical data
Formula	C6480H9992N1716O2042S46
Molar mass	146083.95 g·mol−1

Evinacumab (REGN1500) is a monoclonal antibody designed for the treatment of dyslipidemia.

This drug was developed by Regeneron Pharmaceuticals, Inc. In phase 1, first-in-human, ascending single-dose, placebo (PBO)-controlled, double-blind study evaluated the safety and efficacy of evinacumab administered subcutaneously (SC) or intravenously (IV) in subjects with elevated TGs (150≤ TG ≤450 mg/dL) and/or LDL-C (≥100 mg/dL). Evinacumab effected dose-responsive reductions in TG (maximum reduction on Day 4) with median % changes from baseline of -1.0% to -75.0% from low to high dose vs +9.0% for PBO IV [p<0.0001]) and LDL-C (mean % changes of LDL-C from baseline on Day 11 were -3.4% to -25.5% from low to high dose vs -0.4% for PBO IV [p=0.0013]).